title: Does treatment duration affect outcome after radiotherapy for prostate cancer?
abstract: OBJECTIVE
  The protraction of external beam radiotherapy (RT) time is detrimental in several disease sites. In prostate cancer, the overall treatment time can be considerable, as can the potential for treatment breaks. We evaluated the effect of elapsed treatment time on outcome after RT for prostate cancer.
  
  
  METHODS
  Between April 1989 and November 2004, 1,796 men with prostate cancer were treated with RT alone. The nontreatment day ratio (NTDR) was defined as the number of nontreatment days divided by the total elapsed days of RT. This ratio was used to account for the relationship between treatment duration and total RT dose. Men were stratified into low risk (n = 789), intermediate risk (n = 798), and high risk (n = 209) using a single-factor model.
  
  
  RESULTS
  The 10-year freedom from biochemical failure (FFBF) rate was 68% for a NTDR <33% vs. 58% for NTDR >/=33% (p = 0.02; BF was defined as a prostate-specific antigen nadir + 2 ng/mL). In the low-risk group, the 10-year FFBF rate was 82% for NTDR <33% vs. 57% for NTDR >/=33% (p = 0.0019). The NTDR was independently predictive for FFBF (p = 0.03), in addition to T stage (p = 0.005) and initial prostate-specific antigen level (p < 0.0001) on multivariate analysis, including Gleason score and radiation dose. The NTDR was not a significant predictor of FFBF when examined in the intermediate-risk group, high-risk group, or all risk groups combined.
  
  
  CONCLUSIONS
  A proportionally longer treatment duration was identified as an adverse factor in low-risk patients. Treatment breaks resulting in a NTDR of >/=33% (e.g., four or more breaks during a 40-fraction treatment, 5 d/wk) should be avoided.
authors.affiliation: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: D'Ambrosio
authors.forename: Tianyu
authors.initials: T
authors.lastname: Li
authors.forename: Eric M
authors.initials: EM
authors.lastname: Horwitz
authors.forename: David Y T
authors.initials: DY
authors.lastname: Chen
authors.forename: Alan
authors.initials: A
authors.lastname: Pollack
authors.forename: Mark K
authors.initials: MK
authors.lastname: Buyyounouski
mesh_terms: D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010808:Physical Examination; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011878:Radiotherapy / Q000379:methods*; D020266:Radiotherapy, Conformal / Q000379:methods*; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome